Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive…

Abstract

B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations are rare (1-2%) in invasive mucinous adenocarcinoma (IMA). The therapeutic effect of dabrafenib combined with trametinib in IMA with BRAF mutations remains unknown. An 82-year-old man with a BRAF V600E mutation was diagnosed with mixed invasive mucinous and nonmucinous adenocarcinoma of the lung (cT4N1M1a, stage IVA) and he was treated with dabrafenib plus trametinib. The treatment effect continued for 14 months, suggesting that combined dabrafenib and trametinib as targeted therapy is a potential treatment option for BRAF V600E mutation-positive mixed invasive mucinous and nonmucinous adenocarcinoma of the lung.

Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
Haruhiko Yamazaki, Nobuyasu Suganuma, Mei Kadoya +3
Endocrine Journal1 Sep 2026Peer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE
Prognostic and clinicopathologic divergence in pulmonary mucinous adenocarcinoma versus nonmucinous adenocarcinoma with a mucin-laden feature.
Fujun Yang, Ke Sun, Zhaoxun Li +8
JTCVS open14 Jul 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
A highly successful case report: a patient with intestinal hepatoid adenocarcinoma and liver metastases achieves excellent efficacy following immune-targeted therapy
Siyu Yu, Zhenjie Dai, Dan Jiang +1
Frontiers in Oncology30 Oct 2026Peer-reviewedCC BY 4.0OncologyFrontiersCrossref
Successful Treatment of Recalcitrant Pyoderma Gangrenosum with Baricitinib in Two Patients with Rheumatoid Arthritis.
Christian Ciolfi, Bernd Raffeiner, Margherita Zen +3
Dermatology practical & conceptual31 Jul 2026Peer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
Successful Treatment of an Atypical Mycobacterial Exit Site Infection in a Patient on Peritoneal Dialysis: A Case Report
Michael Shye, Anita D Sircar, Ramya Malchira +2
Cureus16 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{kakiuchi2026successful,
  title = {{Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report}},
  author = {Yosuke Kakiuchi and Miyu Imai},
  journal = {Internal Medicine},
  year = {2026},
  month = jul,
  doi = {10.2169/internalmedicine.7575-26},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7575-26/_article},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report
AU  - Yosuke Kakiuchi
AU  - Miyu Imai
PY  - 2026
DA  - 2026/07/11
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.7575-26
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7575-26/_article
AB  - B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations are rare (1-2%) in invasive mucinous adenocarcinoma (IMA). The therapeutic effect of dabrafenib combined with trametinib in IMA with BRAF mutations remains unknown. An 82-year-old man with a BRAF V600E mutation was diagnosed with mixed invasive mucinous and nonmucinous adenocarcinoma of the lung (cT4N1M1a, stage IVA) and he was treated with dabrafenib plus trametinib. The treatment effect continued for 14 months, suggesting that combined dabrafenib and trametinib as targeted therapy is a potential treatment option for BRAF V600E mutation-positive mixed invasive mucinous and nonmucinous adenocarcinoma of the lung.
SN  - 1349-7235
SN  - 0918-2918
ER  -

Abstract

Related

Cite